Skip to main content

Erdafitinib Side Effects

Medically reviewed by Drugs.com. Last updated on Nov 21, 2023.

Applies to erdafitinib: oral tablet.

Serious side effects of Erdafitinib

Along with its needed effects, erdafitinib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking erdafitinib:

More common

Less common

Rare

Other side effects of Erdafitinib

Some side effects of erdafitinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to erdafitinib: oral tablet.

Hematologic

Very common (10% or more): Hemoglobin decreased (35%), platelets decreased (19%), leukocytes decreased (17%), neutrophils decreased (10%)[Ref]

Musculoskeletal

Very common (10% or more): Musculoskeletal pain (e.g., back pain, musculoskeletal discomfort, musculoskeletal pain, musculoskeletal chest pain, neck pain, pain in extremity) (20%), arthralgia (11%)

Ocular

Very common (10% or more): Dry eye (28%), central serous retinopathy/retinal pigment epithelial detachment (CSR/RPED) (25%), dry eye (e.g., dry eye, xerophthalmia, keratitis, foreign body sensation, corneal erosion) (28%), vision blurred (17%), conjunctivitis (11%), lacrimation increased (10%)

Common (1% to 10%): CSR/RPED involving central field of vision[Ref]

Metabolic

(76%), sodium decreased (40%), decreased appetite (38%), magnesium decreased (30%), phosphate decreased (24%), calcium increased (22%), potassium increased (16%), weight loss (e.g., weight loss, cachexia) (16%), fasting glucose increased (10%)[Ref]

Genitourinary

Very common (10% or more): Urinary tract infection (17%), hematuria (11%)[Ref]

Hepatic

Very common (10% or more): Alanine aminotransferase increased (41%), alkaline phosphatase increased (41%), aspartate aminotransferase increased (30%)[Ref]

Respiratory

Very common (10% or more): Dyspnea (10%)[Ref]

Other

Very common (10% or more): Fatigue (e.g., asthenia, fatigue, lethargy, malaise) (54%), pyrexia (14%)

Frequency not reported: Embryofetal toxicity[Ref]

Nervous system

Very common (10% or more): Dysgeusia (37%)[Ref]

Renal

Very common (10% or more): Creatinine increased (52%)[Ref]

Dermatologic

Very common (10% or more): Onycholysis (e.g., onycholysis, onychoclasis, nail disorder, nail dystrophy, nail ridging) (41%), dry skin (e.g., dry skin, xerostomia) (34%), palmar-plantar erythrodysesthesia (26%), alopecia (26%), paronychia (17%), nail discoloration (11%)[Ref]

Gastrointestinal

Very common (10% or more): Stomatitis (56%), diarrhea (47%), dry mouth (45%), constipation (28%), abdominal pain (e.g., abdominal pain, abdominal discomfort, abdominal pain upper, abdominal pain lower) (23%), nausea (21%), vomiting (13%), oropharyngeal pain (11%)[Ref]

References

1. Product Information. Balversa (erdafitinib). Janssen Products, LP. 2019.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.